We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+6.84%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.79B
AUM Growth
-$153M
(-7.9%)
Cap. Flow
-$217M
Cap. Flow
% of AUM
-12.08%
Top 10 Holdings %
Top 10 Hldgs %
46.91%
Holding
72
New
23
Increased
11
Reduced
17
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$129M |
| 2 |
Pfizer
PFE
|
+$97.3M |
| 3 |
Bausch Health
BHC
|
+$87.4M |
| 4 |
Keysight
KEYS
|
+$66.8M |
| 5 |
Illumina
ILMN
|
+$63.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$96.7M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
+$95.4M |
| 3 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$73M |
| 4 |
Intuitive Surgical
ISRG
|
+$69.4M |
| 5 |
Danaher
DHR
|
+$68.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.97% |
| 2 | Technology | 3.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNK
1
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $131M | 7.31% |
1,325,000
-475,000
| -26% | -$43.7M |
|
|
2
Gilead Sciences
GILD
$163B
| $118M | 6.57% |
+1,250,000
| New | +$129M |
|
|
3
Pfizer
PFE
$142B
| $100M | 5.59% |
+3,392,931
| New | +$97.3M |
|
|
4
Bausch Health
BHC
$2.25B
| $93M | 5.19% |
+650,000
| New | +$87.4M |
|
5
CALL
Agilent Technologies
A
$39.2B
| $73.7M | 4.11% |
1,800,000
+1,101,000
| +158% | +$44.4M |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $72.2M | 4.02% |
5,600,000
+2,025,000
| +57% | +$25.3M |
|
|
7
Keysight
KEYS
$53.4B
| $69M | 3.85% |
+2,043,826
| New | +$66.8M |
|
|
8
Illumina
ILMN
$31B
| $64.6M | 3.6% |
+359,800
| New | +$63.4M |
|
|
SLXP
9
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $60.3M | 3.36% |
525,000
-410,100
| -44% | -$49.7M |
|
10
Labcorp
LH
$25.9B
| $59.3M | 3.31% |
+640,200
| New | +$56.5M |
|
|
MDVN
11
DELISTED
MEDIVATION, INC.
MDVN
| $57.3M | 3.19% |
1,150,000
+100,000
| +10% | +$5.2M |
|
12
Thermo Fisher Scientific
TMO
$214B
| $50.1M | 2.79% |
400,000
+344,700
| +623% | +$41.9M |
|
13
Universal Health Services
UHS
$9.88B
| $50.1M | 2.79% |
450,000
-50,000
| -10% | -$5.25M |
|
|
OCR
14
DELISTED
OMNICARE INC
OCR
| $49.2M | 2.74% |
675,000
+325,000
| +93% | +$22.1M |
|
|
WBMD
15
DELISTED
WebMD Health Corp.
WBMD
| $48.4M | 2.7% |
1,225,000
-56,200
| -4% | -$2.16M |
|
16
Boston Scientific
BSX
$68.4B
| $45.9M | 2.56% |
+3,461,200
| New | +$44.2M |
|
17
CALL
Zimmer Biomet
ZBH
$18.4B
| $45.4M | 2.53% |
+412,000
| New | +$43.4M |
|
|
AVNS
18
DELISTED
Avanos Medical
AVNS
| $43.2M | 2.41% |
+950,800
| New | +$37.4M |
|
|
19
Intuitive Surgical
ISRG
$126B
| $40.5M | 2.26% |
689,400
-1,245,600
| -64% | -$69.4M |
|
20
Viatris
VTRS
$20.7B
| $39.4M | 2.2% |
698,800
-851,200
| -55% | -$45.7M |
|
|
TSRO
21
DELISTED
TESARO, Inc.
TSRO
| $39M | 2.18% |
1,050,000
-148,795
| -12% | -$4.59M |
|
22
McKesson
MCK
$101B
| $36.5M | 2.03% |
175,600
-99,400
| -36% | -$20.2M |
|
|
NUVA
23
DELISTED
NuVasive, Inc.
NUVA
| $35.4M | 1.97% |
750,000
-450,000
| -38% | -$18.8M |
|
|
24
CALL
Danaher
DHR
$138B
| $34.3M | 1.91% |
+595,133
| New | +$32.3M |
|
25
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
| $34.2M | 1.91% |
500,000
-500,000
| -50% | -$33.5M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2014 Portfolio in Review
As of Q4 2014, HealthCor Management held 72 positions worth $1.79B, down 7.9% from $1.95B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HealthCor Management withdrew a net $217M in Q4 2014, closing 20 positions and reducing 17 holdings. Its most notable exit was Veradigm Inc. Common Stock, an estimated $96.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 64% a quarter earlier, followed by Technology.
Against the trend, HealthCor Management opened a new position in Gilead Sciences worth $118M.
- HealthCor Management's largest Q4 2014 buy was Gilead Sciences: 1,250,000 shares worth $118M.
- HealthCor Management added most to Thermo Fisher Scientific in Q4 2014, an estimated $41.9M increase.
- HealthCor Management's biggest Q4 2014 reduction was Intuitive Surgical, cutting an estimated $69.4M.
- HealthCor Management fully exited Veradigm Inc. Common Stock in Q4 2014, selling an estimated $96.7M.
- HealthCor Management's ten largest holdings make up 47% of its $1.79B portfolio in Q4 2014.
- HealthCor Management opened 23 new positions and closed 20 in Q4 2014.
- HealthCor Management's portfolio value fell 7.9% quarter-over-quarter to $1.79B.
Based on HealthCor Management's 13F filing for Q4 2014, filed 17 Feb 2015.